A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT07518186)

🧪 Interventions in This Study

• JNJ-79635322 (DRUG)
• Teclistamab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (151 Sites)

Showing the first 25 of 151 sites.

• Alabama Oncology — Birmingham, Alabama
• Mayo Clinic 1 — Phoenix, Arizona
• Highlands Oncology Group — Springdale, Arkansas
• Beverly Hills Cancer Center Clinical Research Advisors LLC — Beverly Hills, California
• UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
• Valkyrie Clinical Trials — Los Angeles, California
• University of California Irvine Medical Center — Orange, California
• Colorado Blood Cancer Institute — Denver, Colorado
• University of Connecticut Health Center — Farmington, Connecticut
• Mayo Clinic Jacksonville — Jacksonville, Florida
• Memorial Cancer Institute — Pembroke Pines, Florida
• Emory University — Atlanta, Georgia
• Rush University System for Health — Chicago, Illinois
• Franciscan Health — Indianapolis, Indiana
• University of Iowa Hospitals and Clinics — Iowa City, Iowa
• Mission Cancer Blood University of Iowa Health Care — Waukee, Iowa
• Norton Cancer Institute — Louisville, Kentucky
• LSU Health Feist Weiller Cancer Center — Shreveport, Louisiana
• Karmanos Cancer Institute — Detroit, Michigan
• University Of Minnesota Medical Center — Minneapolis, Minnesota
• Mayo Clinic — Rochester, Minnesota
• Nebraska Cancer Specialists — Omaha, Nebraska
• Astera Cancer Care — East Brunswick, New Jersey
• Christus St. Vincent Regional Cancer Center — Santa Fe, New Mexico
• New York Oncology Hematology — Albany, New York

📞 Contact the Study Coordinator

Phone: (844) 434-4210

Email: Participate-In-This-Study1@its.jnj.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.